Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

EMA Identifies Steps To Foster ATMP Development

Executive Summary

EU biotech companies have welcomed the various initiatives that the European Medicines Agency has listed to support the development of advanced therapy medicinal products. However, they want clear timelines on completing these initiatives since their implementation will not require any changes to the current legislative framework.

Advertisement

Related Content

Concerns Over Format Of EU GMP Guideline For ATMPs Finally Resolved; Publication Due
Gene Therapy Trials In EU Delayed By Environmental Considerations
EMA's Action Plan To Support ATMPs Expected In Jan 2017
EMA Works On Definition To Support Similarity Assessments For Orphan Drugs
Five years, two products: is the EU's advanced therapies legislation working?

Topics

Advertisement
UsernamePublicRestriction

Register

PS120036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel